Research Summary

As a urologic oncologist, my practice is primarily focused on the surgical management of individuals with genitourinary cancers. My research has been focused primarily on clinical research related to outcomes, with an emphasis on access to care and disparities in receipt of healthcare for individuals with prostate and bladder cancer.

Research Funding

  • December 2, 2021 - November 30, 2024 - An Atlas of Human Prostate AcrossAncestries to develop a comprehensive atlas of the human pros-tate at single-cell resolution with a community engagement plan to maximize impact for the public and clinical and scientific communities , Co-Principal Investigator . Sponsor: Chan Zuckerberg Initiative DAF, Sponsor Award ID: P0559192
  • December 1, 2021 - November 30, 2022 - Drivers of racial disparities in management of advanced prostate cancer: examining local and geo-graphic variations in evaluation and treatment. , Principal Investigator . Sponsor: ConcertAI, Sponsor Award ID:
  • October 1, 2019 - October 1, 2020 - Impact of socioeconomic status on overutilization of healthcare expenditure in patients with bladder cancer , Co-Investigator . Sponsor: OptumLabs, Sponsor Award ID: 20183
  • July 1, 2018 - June 30, 2019 - The Differential Impact of Race on Oncologic Outcomes in Elderly Patients with Bladder Cancer: A Population-based Study , Co-Principal Investigator . Sponsor: NIA RCMAR/UCSF Center for Aging in Diverse Communities Scholars Program, Sponsor Award ID: 132016C

Education

  • University of California, Davis, BS, 2007, Genetics
  • University of California, San Francisco, MD, 2012
  • University of California, San Francisco, MOTH, 2019, Masters of Advanced Study in Clinical Research
  • University of California, San Francisco, Resident, 2018, Urology
  • University of California, San Francisco, Postdoctoral Fellow, 2020, Urologic Oncology

Honors & Awards

  • 2021 - 2022
    Engaging Research to Achieve Cancer Care Equity (ERACE) Research Award, ConcertAI
  • 2021
    Goldberg-Benioff Endowed Professorship in Cancer Biology, University of California, San Francisco
  • 2021
    Grunfeld Scholar, San Francisco VA Healthcare System Research Development Initiative
  • 2021
    John A. Watson Faculty Scholar, Dean's Diversity Fund, University of California, San Francisco
  • 2019 - 2020
    OptumLabs Health Data for Action: Leveraging Health Data for Actionable Insights Data Access Award, OptumLabs
  • 2018 - 2019
    UCSF CADC Scholar, UCSF Center for Aging in Diverse Communities
  • 2010 - 2011
    Pathways to Careers in Clinical and Translational Research Yearlong Fellowship, University of California, San Francisco
  • 2009 - 2009
    Dean's Summer Research Fellowship, University of California, San Francisco

Selected Publications

  1. Washington SL. EDITORIAL COMMENT. Urology. 2022 Apr; 162:26.  View on PubMed
  2. Greenberg SA, Cowan JE, Lonergan PE, Washington SL, Nguyen HG, Zagoria RJ, Carroll PR. The effect of preoperative membranous urethral length on likelihood of postoperative urinary incontinence after robot-assisted radical prostatectomy. Prostate Cancer Prostatic Dis. 2022 Feb; 25(2):344-350.  View on PubMed
  3. Leapman MS, Dinan M, Pasha S, Long J, Washington SL, Ma X, Gross CP. Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer. JAMA Oncol. 2022 Mar 03.  View on PubMed
  4. Chappidi MR, Bell A, Cowan JE, Greenberg SA, Lonergan PE, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer. J Urol. 2022 05; 207(5):1001-1009.  View on PubMed
  5. Washington SL, Gore JL, Nyame YA. Translating Patient-Centered Research into Educational Resources to Address Racial Inequities in Prostate Cancer. J Urol. 2022 03; 207(3):496-497.  View on PubMed
  6. Lonergan PE, Washington SL, Cowan JE, Zhao S, Broering JM, Cooperberg MR, Carroll PR. Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer. J Urol. 2022 04; 207(4):832-840.  View on PubMed
  7. Lonergan PE, Jeong CW, Washington SL, Herlemann A, Gomez SL, Carroll PR, Cooperberg MR. Active surveillance in intermediate-risk prostate cancer with PSA 10-20‚ÄČng/mL: pathological outcome analysis of a population-level database. Prostate Cancer Prostatic Dis. 2021 Sep 10.  View on PubMed
  8. Zheng MY, Overland M, Escobar D, Fakunle M, Li Y, Chu C, Balakrishnan A, Shee K, Washington S, Hampson L. Formal Mentorship as an Opportunity to Expand the Urology Pipeline: Under Represented Trainees Entering Residency (UReTER) Program Evaluation 2020-2021. Urology. 2021 Sep 08.  View on PubMed
  9. Simons ECG, Arevalo A, Washington SL, Does S, Kwan L, Nguyen AV, Downs TM, Braddock CH, Saigal C. Trends in the Racial and Ethnic Diversity in the US Urology Workforce. Urology. 2021 Aug 29.  View on PubMed
  10. Bell A, Lonergan PE, Escobar D, Fakunle M, Chu CE, Berdy S, Palmer NR, Breyer BN, Washington SL. A Cross-Sectional Analysis of Barriers Associated With Non-Attendance at a Urology Telehealth Clinic in a Safety-Net Hospital. Urology. 2022 Apr; 162:57-62.  View on PubMed
  11. Greenberg SA, Washington SL. The state of our understanding of prostate cancer in sub-Saharan Africa. Cancer. 2021 11 15; 127(22):4131-4132.  View on PubMed
  12. Lonergan PE, Cowan JE, Washington SL, Greenberg SA, Nguyen HG, Carroll PR. Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort. Prostate. 2021 09; 81(13):1009-1017.  View on PubMed
  13. Greenberg SA, Washington SL, Lonergan PE, Cowan JE, Baskin AS, Nguyen HG, Odisho AY, Simko JP, Carroll PR. Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen. J Urol. 2021 09; 206(3):706-714.  View on PubMed
  14. Langlais CS, Graff RE, Van Blarigan EL, Palmer NR, Washington SL, Chan JM, Kenfield SA. Post-Diagnostic Dietary and Lifestyle Factors and Prostate Cancer Recurrence, Progression, and Mortality. Curr Oncol Rep. 2021 03 10; 23(3):37.  View on PubMed
  15. Washington SL, Nyame YA. EDITORIAL COMMENT. Urology. 2021 02; 148:209-210.  View on PubMed
  16. Chu CE, Cowan JE, Lonergan PE, Washington SL, Fasulo V, de la Calle CM, Shinohara K, Westphalen AC, Carroll PR. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer. Eur Urol Oncol. 2021 Jan 19.  View on PubMed
  17. Downs TM, Enemchukwu E, Lee CT, Moses KA, Nyame YA, Powell IJ, Vince R, Williams H, Wilson S, Washington SL. Supporting Black voices in urology. Nat Rev Urol. 2021 01; 18(1):7-17.  View on PubMed
  18. Chu CE, Law L, Zuniga K, Lin TK, Tsourounis C, Rodriguez-Monguio R, Lazar A, Washington SL, Cooperberg MR, Greene KL, Carroll PR, Pruthi RS, Meng MV, Chen LL, Porten SP. Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical Cystectomy. Urology. 2021 Mar; 149:168-173.  View on PubMed
  19. Washington SL, Jeong CW, Lonergan PE, Herlemann A, Gomez SL, Carroll PR, Cooperberg MR. Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US. JAMA Netw Open. 2020 12 01; 3(12):e2031349.  View on PubMed
  20. Chu CE, Cowan JE, Fasulo V, Washington SL, de la Calle C, Shoemaker J, Carroll PR. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide? J Urol. 2021 Jan; 205(1):109-114.  View on PubMed

Go to UCSF Profiles, powered by CTSI